Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.

Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs endothelial corneal dystrophy market. The report highlights a surge in market ...

In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...

Design Therapeutics will present DT-168 program updates for Fuchs endothelial corneal dystrophy at Eyecelerator on May 2, 2025.

In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscular weakness and mild intellectual disability.

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research.

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when bought Kate Therapeutics, the pharma’s CEO said.

Fuchs' dystrophy is an inherited condition affecting the cornea that can cause impaired vision and discomfort, but treatments are available.